Follow
Shoya Iwanami
Shoya Iwanami
Division of Natural Science, Graduate School of Science, Nagoya University, Japan
Verified email at f.mail.nagoya-u.ac.jp - Homepage
Title
Cited by
Cited by
Year
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment
H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ...
Iscience 24 (4), 102367, 2021
99*2021
A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2
KS Kim, K Ejima, S Iwanami, Y Fujita, H Ohashi, Y Koizumi, Y Asai, ...
PLoS biology 19 (3), e3001128, 2021
63*2021
Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study
S Iwanami, K Ejima, KS Kim, K Noshita, Y Fujita, T Miyazaki, S Kohno, ...
PLoS medicine 18 (7), e1003660, 2021
24*2021
Estimation of the incubation period of COVID-19 using viral load data
K Ejima, KS Kim, C Ludema, AI Bento, S Iwanami, Y Fujita, H Ohashi, ...
Epidemics 35, 100454, 2021
24*2021
Inferring timing of infection using within-host SARS-CoV-2 infection dynamics model: are “Imported Cases” Truly Imported?
K Ejima, KS Kim, Y Ito, S Iwanami, H Ohashi, Y Koizumi, K Watashi, ...
MedRxiv, 2020
172020
A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture
S Iwanami, Y Kakizoe, S Morita, T Miura, S Nakaoka, S Iwami
Theoretical Biology and Medical Modelling 14 (1), 1-13, 2017
142017
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
K Shionoya, M Yamasaki, S Iwanami, Y Ito, S Fukushi, H Ohashi, W Saso, ...
Frontiers in microbiology 12, 651403, 2021
112021
Revisiting the guidelines for ending isolation for COVID-19 patients
YD Jeong, K Ejima, KS Kim, S Iwanami, AI Bento, Y Fujita, IH Jung, ...
Elife 10, e69340, 2021
82021
Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model
K Ejima, KS Kim, S Iwanami, Y Fujita, M Li, RS Zoh, K Aihara, T Miyazaki, ...
Journal of the Royal Society Interface 18 (177), 20200947, 2021
52021
Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24, 102367 (2021)
H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa
52021
Multidrug treatment with nelfinavir and cepharanthine against COVID-19. bioRxiv. 2020
H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ...
April 15 (10.1101), 2020.04, 2020
52020
Quantitative Immunology by Data Analysis Using Mathematical Models
S Iwanami, S Iwami
Encyclopedia of Bioinformatics and Computational Biology 2, 984-992, 2019
52019
Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma
S Iwanami, K Kitagawa, H Ohashi, Y Asai, K Shionoya, W Saso, ...
PLoS biology 18 (7), e3000562, 2020
42020
Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey
M Yoshida, Y Kobashi, T Kawamura, Y Shimazu, Y Nishikawa, F Omata, ...
Vaccines 10 (4), 515, 2022
32022
Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection
KS Kim, S Iwanami, T Oda, Y Fujita, K Kuba, T Miyazaki, K Ejima, S Iwami
Life science alliance 4 (10), 2021
32021
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2
H Ohashi, T Hishiki, D Akazawa, KS Kim, J Woo, K Shionoya, ...
bioRxiv, 2022
12022
Characterization of various remdesivir-resistant mutations of SARS-CoV-2 by mathematical modeling and molecular dynamics simulation
S Torii, KS Kim, J Koseki, R Suzuki, S Iwanami, Y Fujita, YD Jeong, ...
bioRxiv, 2022
12022
Revealing uninfected and infected target cell dynamics from peripheral blood data in highly and less pathogenic simian/human immunodeficiency virus infected Rhesus macaque
A Hara, S Iwanami, Y Ito, T Miura, S Nakaoka, S Iwami
Journal of Theoretical Biology 479, 29-36, 2019
12019
Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection
R Kumata, S Iwanami, KB Mar, Y Kakizoe, N Misawa, S Nakaoka, ...
PLoS computational biology 18 (4), e1010053, 2022
2022
Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan
N Nakamura, Y Kobashi, KS Kim, Y Tani, Y Shimazu, T Zhao, ...
medRxiv, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–20